Analysis of the effects of apomorphine and bulbocapnine in relation to the proposed dopamine receptor.
D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects; D001058:Apomorphine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D001060:Aporphines / Q000494:pharmacology*; D004149:Dioxoles / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology*; D018492:Dopamine Antagonists; D004305:Dose-Response Relationship, Drug; D004336:Drug Antagonism; D006168:Guinea Pigs; D006325:Heart Atria / Q000187:drug effects; D006632:Histamine / Q000494:pharmacology; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D010646:Phentolamine / Q000494:pharmacology; D010656:Phenylephrine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D011955:Receptors, Drug / Q000187:drug effects*; D013618:Tachyphylaxis / Q000187:drug effects; D014649:Vas Deferens / Q000187:drug effects
D001060:Aporphines; D004149:Dioxoles; D018492:Dopamine Antagonists; D011955:Receptors, Drug; D010656:Phenylephrine; D006632:Histamine; D007545:Isoproterenol; D001058:Apomorphine; D004298:Dopamine; D010646:Phentolamine